Q3 2023 Cibus Inc Earnings Call
Operator 3: Good afternoon, and welcome to the Cibus Q3 2023 results conference call. At this time, I'd like to turn the conference over to Wade King, Chief Financial Officer. Sir, please go ahead.
Speaker 1: Good afternoon and welcome to the CBIS third quarter 2023 results conference call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. At that time, if you have a question, please press the one followed by the four on your telephone keypad. If at any time during the conference you need to reach an operator, please press star zero. Please also note today's event is being recorded. At this time, I'd like to turn the conference over to Wade King, chief financial officer, sir, please go ahead.
Good afternoon, and welcome to the <unk> third quarter 2023 results conference call all participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions at that time. If you have a question. Please press the one followed by the four on your telephone keypad.
If at any time during the conference you need to reach an operator. Please press Star Zero. Please also note today's event is being recorded at this time I'd like to turn the conference over to Wade King Chief Financial Officer, Sir. Please go ahead.
Wade King: Thank you, and good afternoon. This is Wade King, the Chief Financial Officer of Cibus. I would like to thank you for taking time to join us for Cibus' Q3 2023 financial results and corporate update conference call and webcast. Presenting with me today is Rory Riggs, our Co-founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-founder, President, and Chief Operating Officer. Before we begin the conference call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Please refer to Cibus' SEC filings for a list of associated risks. This conference call is being webcast.
Thank you and good afternoon.
Speaker 2: This is Wade King, the Chief Financial Officer of Cebus. I would like to thank you for taking time to join us for Cebus third quarter, 2023 financial results and corporate update conference call and webcast.
It's just we'd king the chief financial officer of cheapest.
I'd like to thank you for taking time to join US for <unk> third quarter 2023 financial results and corporate update conference call and webcast.
Speaker 2: Presenting with me today is Rory Riggs, our Co-Founder, Chief Executive Officer and Chairman and Peter Beeson, Co-Founder, President and Chief Operating Officer.
Sitting with me today is worrying breaks our co founder and Chief Executive Officer and Chairman.
And Peter Beaven, co founder President and Chief operating Officer.
Speaker 2: Before we begin the conference call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, a forward looking and maybe subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call.
Before we begin the conference call I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects are forward looking and maybe subject to a number of risks and uncertainties.
That could cause actual results could differ materially from those described in the call.
Speaker 2: please refer to SEVIS SEC filings for a list of associated risks. This conference call is being webcast. The webcast link along with our press release and corporate presentation are available on the investor relations section of SEVIS.com to assist in your analysis of the business. With that, I would now like to turn the call over to Mr. Riggs. Go ahead, Rory.
So you just prefer to see this FCC filings for a list of associated risks.
This conference call is being webcast the webcast link along with our press release and corporate presentation are available on the Investor Relations section of <unk> Dot com to assist in your analysis of the business with that I would now like turn the call over to Mr. Rick.
Wade King: The webcast link, along with our press release and corporate presentation, are available on the investor relations section of cibus.com to assist in your analysis of the business. With that, I would now like to turn the call over to Mr. Riggs. Go ahead, Rory.
Go ahead Larry.
Speaker 3: Thanks Wade and welcome to every video on the call. I'll begin by highlighting several of our recent business and commercial updates. Then Peter and I will walk you through where we are and where we are headed.
Rory Riggs: Thanks, Wade. Welcome to everybody on the call. I'll begin by highlighting several of our recent business and commercial updates. Peter and I will walk you through where we are and where we are headed. Lastly, Wade will finish with a brief discussion of the financials. The goal of this format is to provide you with an educational overview of our business, its pipeline, and their prospects so that you're better equipped with a solid foundation to better understand our company and to track our events and progress. With that, I'd like to discuss some of our recent business and commercial updates. Since going public in June of this year, we have been laser-focused on driving our evolution from an R&D company to a commercial company.
Thanks, Wade and welcome to everybody on the call I'll begin by highlighting several of our recent business or commercial updates then Peter and I will walk you through where we are and where we are headed.
Speaker 3: Lastly, Wade will finish with a brief discussion of the financials. The goal of this format is to provide you with an educational overview of our business. It's pipeline and their prospects. So you better equipped with a solid foundation to better understand our company, and to track our events and progress.
Lastly, Wade will finish with a brief discussion of the financials. The goal of this format is to provide you with an educational overview of our business pipeline and their prospects.
Who better equipped with a solid foundation.
Understand our company.
And to track our events and progress.
Speaker 3: With that, I'd like to discuss some of our recent business and commercial updates.
With that I'd like to discuss some of our recent business like commercial updates.
Speaker 3: Since going public in June of this year, we have been laser-focused on driving our evolution from an R&D company to a commercial company.
Since going public in June of this year, we have been laser focused on driving our evolution from an R&D company to a commercial company.
Rory Riggs: As parts of this transition, we underwent a strategic alignment in October aimed at bringing enhanced focus to our primary commercial goal, which is furthering the advancement of our commercial activities. All of our resources and operations are now centered on completing the launch of our initial traits. Importantly, our three developed traits, pod shatter reduction, often referred to as PSR in canola, and in rice, HT1, herbicide tolerance number 1, and HT3, herbicide tolerance number 3, as well as the advancement of our soybean platform and bolstering the development of our advanced traits, Sclerotinia resistance and HT2 in both canola and soybean. Notably, our realigned efforts have captured this focus and priorities. I'll speak to our progress on each of these traits a little later on.
Speaker 3: As part of this transition, we underwent a strategic alignment in October , aimed at bringing enhanced focus to our primary commercial goal, which is further in the advancement of our commercial activity.
There's parts of this transition we underwent a strategic alignment and October aimed at bringing focus to our primary commercial goal, which is furthering the advancement of our commercial activities.
Speaker 3: All of our resources and operations are now centered on completing the launch of our initial trade.
All of our resources and operations are all centered on completing the launch of our initial trace importantly, our three volt trades hotshot reduction also referred to as <unk>.
Speaker 3: importantly, a three developed traits, pod-shattered reduction, often referred to as PSR in Camila. And in LIS, HT-1, Riverside Tallah, number one, and HT-3, who is I challenge number three, as well as the advancement of our soybean platform and bolstering these development, for our advanced traits.
And then the lice HD one herbicide tolerance.
Q3, who is I would call a separate REIT.
As well as the advancement of our soybean platform and bolstering its development grants trades screws or assistance and HQ2.
Speaker 3: parasinia resistance and HG2 in both canola and soybean.
Canola and soybean.
Notably.
Speaker 3: Our realigned efforts have captured this focus in priorities. I'll speak to our progress each of these traits a little later off.
Our realized efforts have captured this focus and priorities.
Speak to our progress in each of these traits a little later on.
Speaker 3: In current weather fatigue, degree alignment, we have also implemented some necessary cost-production measures with the objectives of preserving capital resources for the advancement of these five traits.
Rory Riggs: Concurrent with our strategic realignment, we have also implemented some necessary cost reduction measures with the objective of preserving capital resources for the advancement of these five traits. We believe that refocusing on our strength and top priorities will position us well to achieve our strategic objectives in a more timely manner. We're working hard to make sure that happens. Let me take you to our five trait, three crop business model. Although royalties haven't started yet, our commercialization efforts are well underway. They are centered around advancing five traits with applications in three major crops, rice, canola, and soybean. Combined, we believe this represents an addressable market opportunity of over 250 million acres and over $1 billion in potential royalties across canola, rice, and soybeans. We believe that this five trait, three crop model is just the beginning of what our capabilities can ultimately address.
Concurrent with our strategic realignment. We are also implementing some necessary cost reduction measures with the objective of preserving capital resources.
Vance.
Five trades.
Speaker 3: We believe that we focusing on our strength and top priorities will position us well to achieve our strategic objectives in a more timely manner. We're working hard to make sure that.
We believe that refocusing on our strengths and top priorities will position us well to achieve our strategic objectives in a more timely manner, we're working hard to make sure that happens.
Speaker 3: So let me take you to our five trade three crop business while although world news haven't started yet, our commercialization efforts are well underway.
So let me take you through our five trades wheat crop business well.
Although royalty that haven't started yet.
Realization efforts are well underway.
Speaker 3: They are centered around advancing five traits with applications in three major crops, rice, canola, and soybean.
They are centered around advancing five trades with applications in the three major crops rice.
Sure.
Yes.
Speaker 3: Combined, we believe this represents an addressable market opportunity of over 250 million acres and over $1 billion in potential royalties across canola, rice, and soybean.
Combined we believe this represents the addressable market opportunity of over 250 million acres in the world.
$1 billion in potential royalties across Coca Cola.
Rice and soybeans.
Speaker 3: We believe that this five-trade, three-crop model is just the beginning of what our capabilities can ultimately achieve.
We believe with just five trades III crop model is just the beginning of what our capabilities can ultimately address.
Rory Riggs: One of our key accomplishments of our scientists has been their mastery of oligonucleotide-directed mutagenesis, our single-cell editing technology, and our production systems supporting each crop platform. For many, the even bigger accomplishment is the fact that with this technology platform, the team at Cibus has been able to generate a product pipeline of five important traits. Three of these traits are fully developed, have multiple years of successful field trials, and strong intellectual property. Important for each trait, we now have a strong customer base. In addition, Cibus has built two crop platforms in canola and rice, as well as being close to a third crop platform in soybean. Our soybean platform has been under active development for several years, and we expect to have the soybean platform operational in Q4 2023.
One of our key accomplishments of our scientists that's been their mastery of Olive garden nuclear corrected me the Genesis, our single cell technology, and our production system supporting each crop platform.
For many even bigger accomplishment.
With this technology platform the team, let's see this was able to generate a pipeline of five important trades three of these traits are fully developed.
Full year successful field trials and strong intellectual property.
First Street, we now have a strong customer base.
In addition, <unk> built two crop platforms that could lower waste as well as being close to a third crop platform as soybean.
Our soybean platform is under active development for several years and we expect to have the soybean platform operational Q4 2023.
Rory Riggs: Now that we have these three traits developed and we've been commercializing them through a high throughput editing process, accelerating our development timeline, we are very excited about the prospects for these three traits. In this process, we edit our customer's proprietary germplasm and then transfer their germplasm back to them with our trait. We can now execute this process very quickly, allowing the customer to accelerate their commercialization process. Once satisfied and the results are confirmed, the customer develops a registration dossier, initiates its marketing plan, bulks up its seed inventory, and ultimately distributes the seed to farmers, at which point the royalties begin being paid to Cibus. We consider our first trait product to be our pod shatter reduction trait, PSR. It strengthens the sheath around the canola seeds, which protects the crops in extreme weather conditions. We have shown PSR's efficacy in multiple field trials.
Now that we have these three creates developed commercializing them through a high throughput is in process.
Celebrating our development timeline for <unk>.
Very excited about the prospects for these 30 trades in this process. We ended our customers' proprietary germplasm and then trials for their germ plasm back to them with our trade we cannot execute this process very quickly, allowing the customer to accelerate the commercialization process.
Satisfied and the results are confirmed then the customer develops or registration dose yet initiated marketing place bulks are going to see the inventory.
Distributes the seed to flowers at which point the royalties again being paid to see this.
We consider our first trade product superior shatter resistant trades <unk> its strengths into seats alone could canola seeds, which protects the crops and extreme weather conditions.
We have shown <unk> efficacy in multiple field trials.
Rory Riggs: Based on these field trials, we now have 10 different customers that we estimate represent over 20 million acres of canola WOSR. We now have edited these crops and have started returning to customers their elite germplasm with our PSR trait. As we have stated, we expect to complete transfers to six customers in 2023. We expect in 2024 to transfer the remaining customers and increase our market penetrations with additional customers. We estimate that the annual trait royalty from PSR could be approximately $200 million annually. In addition to PSR, the two developed traits are HT1 and HT3 in rice. They are important gene-edited traits for herbicide tolerance or weed management. Over 95% of canola, soybean, and corn currently utilize GMO-based herbicide traits for weeds management. Rice has never had GMO traits. This is why these two traits are in high demand in rice.
Based on these field trials, we now have 10 different customers. So we estimate represent over 20 million acres lower W. L. A S R.
We now have these crops and have started returning to customers or at least germ plasm with Rps are true.
As we have stated that we expect to complete transfers to six customers in 2023. Additionally, we expect in 'twenty four.
That's where the remaining customers and increase our market penetration with additional customers, we estimate that the annual world Central <unk> could be approximately $200 million.
In addition to <unk> with to develop trades, our HD one HD three in the race.
They're important genomic trades for herbicide tolerance or we'd manage works.
Over 95% of canola soybean corn currently utilized GMO based herbicide trades through each management.
<unk> never had GMO trades. This is why these two Tracy French Fry demand in rice, we have already transferred our first HD one HD three traits in rice to neutral for the North American market.
Rory Riggs: We have already transferred our first HT1, HT3 traits in rice to Nutrien for the North American market. We now have three customers who we believe represent over 4 million acres in North and South America. We expect additional customers in North America and South America in 2024. We estimate that the annual trait royalties for use from HT1, HT3 in rice could be approximately $150 million a year. These HT traits are now fully developed and validated, and similar to our work in PSR, we'll be tracking the progression to customers' commercial lines that will generate our future royalty streams. The progression of these three traits has accelerated significantly in 2023. We are shipping edited traits back to customers and are also adding new customers across both canola and soybean.
Now have three customers, who we believe represent over 4 million acres in north and South America.
We expect additional customers in North America, and South America in 2024, we estimate that the annual trade Worldview three is for <unk> three in ways could be approximately $115 million a year.
When you say street rates are now fully developed and validated and similar to our work in <unk>, we'll be tracking to progression to customers commercial lines that will generate our future royalty streams.
The progression of these III trades has accelerated significantly in 2023, we're shifting as it trades back to customers are also.
For us across both canola and soybean we look forward to updating you on the progress of these three trades in these two crops over the preceding quarters.
Rory Riggs: We look forward to updating you on the progress of these three traits in these two crops over proceeding quarters. In addition to our developed traits, our two advanced traits are critically important. They are both multi-crop traits, meaning they have potential efficacy across multiple crop types. The first advanced trait is HT2, or herbicide tolerance number two for weed management. Because of the extensive overuse of certain modes of action over the last 20 years, many weeds have become resistant to those herbicides. For crops like canola and soybean, there is extensive demand for new broad-spectrum herbicides and associated herbicide traits that target broadleaf weeds. That is the market for HT2. We expect important greenhouse results next summer for this trait. Because of its demand in both canola and soybean, we believe it has the potential to be the first gene-edited trait to exceed 100 million acres.
In addition to our developed trades are two advanced traits are critically important there.
They are both multi crop traits, meaning they have potential efficacy across multiple crop types.
The first advance tree is H T two or herbicide resistant number two for weed management.
Because of the extensive overuse of certain modes of action over the last 20 years, many weeds have become resistant to those herbicides for crops like canola soybean dense.
Hence the demand for new broad spectrum, herbicides and associated herbicide trades.
<unk>.
I believe that as the market for HD too.
We expect important greenhouse results next summer for this trait.
Because of its demand both canola and soybean we believe that's a potential.
The first.
Trade to exceed 100 million acres.
Rory Riggs: For perspective, the industry estimates that GMO-based herbicide traits are utilized currently on over 300 million planted acres. The second advanced trait is for Sclerotinia or white mold resistance. Sclerotinia is the most damaging disease in canola and one of the major diseases impacting soybean. As a disease trait, this is not a single mode of action trait. In order to be durable, this trait needs to address multiple parts of the disease condition. If successful, this would be the first major disease trait that be applicable to multiple crops. If this trait is successful and deployed across both canola and soybean, we believe that this trait has the potential to be the largest gene-edited trait to date. The development of these two traits have progressed well in 2023.
The industry estimates of GMO based herbicide trades are utilized currently over 300 million planted acres.
The second advanced trade it for square kidney or white mold resistance.
<unk> is the most damaging disease in canola and one of the major diseases impacting soybean.
As it illustrates this is not a single motive action trade in order to be durable this trade needs to address multiple parts of the disease condition. If successful this would be the first major disease trip applicable to multiple crops.
This trade is successful and deployed across both canola and soybean. We believe that this trade has the potential to be the largest trade to date.
The development of these two trades have progressed well in 2023 over the next year as we will track the progression of these two trades also and their advancement to customers commercial lives into the royalty payments.
Rory Riggs: Over the next years, we will track the progression of these two traits also and their advancement to customers' commercial lines and to their royalty payments. These traits and their royalty payments will be a significant component of our economic base and profitability. We will follow this progress on a quarterly basis very closely. Soybean is the last component of our five trait, three crop business plan. We have had significant progress in completing our soybean single cell editing platform. As we have stated, we still believe that we will complete development of this platform in FY 2023. Over the next few years, we will track the progression of our soybean business. Once we have achieved our platform, we expect to have significant growth in soybean customers based on initial discussions we have had to date. This is a large 200-million-plus acre crop in just North and South America.
These trades and their royalty payments will be a significant component of our economic base and profitability. We will follow this progress on a quarterly basis very closely.
Soybean is the last component of our five grade III crop business, where we.
We've had significant progress in completing our soybean single cell editing platform.
As we have stated we still believe that we will complete development of its platform of FY 2023.
Over the next few years, we will track the progression of our soybean doses. Once we have achieved our platform. We expect significant growth in soybean customers based on initial discussions we have had to date.
This is a large toward million plus acre crop.
North and South America.
Rory Riggs: Many of the major soybean seed companies are already customers of Cibus in other crops. We believe that soybeans will be a major contributor of our economic space going forward and a central pillar of the growth of gene editing in agriculture. As is clear, our five trait, three crop model is the central focus of our corporate strategy. We intend to track the progression of each trait as is deployed in elite germplasm, and the progression of each will be central to our quarterly updates going forward as each trait by crop combination starts generating royalty revenue. With that, I'd like to pass the call over to Peter for his remarks.
Many of the major soybean seed companies are already customers you see those other crops. We believe that soybean will be a major contributor of our economics basically forward.
Pillar of the growth of gene editing that group culture.
As is clear.
Five trade three crop model as the central focus of our corporate strategy.
We intend to track the progression of each trade is deployed into elite germplasm and the progressive each will be central to our quarterly updates going forward as each trade by crop combinations starts generating royalty revenue.
With that I'd like to pass the call over to Peter for his remarks.
Peter Beetham: Thank you, Rory, and good afternoon to everybody. As Rory just mentioned, Cibus' five trait, three crops model is at the forefront of agriculture's analog to digital moment. We say that because with these gene-edited traits, we are fundamentally changing the scale and speed of trait development in crops. The technologies behind our Rapid Trait Development System, RTDS, allows us to edit a single cell extracted from plants that represent the best plant genetics in the industry. We term this as elite germplasm. The edited cells from that elite germplasm are then regenerated into an identical elite germplasm with the targeted edits. This really is the key point of differentiation at Cibus from other gene editing technologies. With it, we have significantly reduced the time and expense of bringing new trait innovations to seed companies. Our focus continues to be scaling and acceleration of customers' gene-edited elite genetics.
And good afternoon to everybody.
It really just mentioned C. This is five three crops model.
At the forefront of agriculture analog to digital alignment, we say that because we think gene editing traits, we are fundamentally changing the scale and speed.
I've tried development in crops.
The technology behind our rapid development system Itbs allows us to address a single cell extracted from clients that represent the best plant genetics in the industry.
10 days.
As a lead Gen platform.
The editor itself from that even Gen then re generated into.
Identical elite germplasm with the targeted edits.
This really is the key point of differentiation at say this from other gene editing technologies.
We have significantly reduced the time and expense of bringing new innovations to seed companies.
Our focus continues to be scaling and acceleration of customers gene edited elite genetics.
Peter Beetham: Here's how high throughput gene editing, AKA our Trait Machine, works. Once we secure approval from the seed company to edit their germplasm and we physically receive the germplasm from them, the developing of a product begins as it enters the Trait Machine. As we shared last quarter, we opened the first high throughput semi-automated gene editing facility. As Rory mentioned, we are excited to see our first customers' edited germplasm transfers in 2023. This new facility is set to deliver additional products at scale and acceleration over the next 24 months. It's important to note that when we add a new trait to our portfolio, we don't have to invest in an entirely new machine. Instead, we simply use a new set of editing reagents.
He is how high throughput gene editing.
Outright machine works.
Once we secure approval and you see company.
Yeah, Jim Polson.
And we physically received the gen plasma farmland, the developing of our product beginning.
Is it answers the Triton machine.
As we stated last quarter, we opened the first high throughput.
What am I to gene editing facility.
As Marty mentioned, we are excited to see our first customer.
Pleasant cancelled in 2023.
And this new facility.
Additional product that skyline acceleration over the next 24 months.
It's important to note that when we add a new trial to Apple falling on we don't have to invest in an entirely new machine.
Instead, we simply use a new set of editing reagents.
Peter Beetham: When we add a new crop to the platform, we just add in plug-and-play automation solutions while applying years of plant tissue culture experience to facilitate any changes that may be required. The relative simplicity of our design and the efficiency that it allows is the basis for our rapid development, while also helping curtail significant CapEx investments as we scale and accelerate our business. When we receive our customer's elite germplasm, it is processed and run through our Trait Machine. Once the molecular confirmation of the edit is complete, we validate the quality of that edit, the efficiency of the trait, and ensure the elite line is identical to what we initially received with the sole exception of the edits we made. This quality assurance is absolutely critical for our customers.
We added new crop to the platform, we just add in plug and play automation solutions, while apply user.
Plant tissue culture experience can facilitate any changes.
Maybe required.
The relative simplicity of Amazon and the efficiency that it allows is the basis for our rapid development.
While also helping cotai all significant capex investments as we scale and accelerate our business.
When do we save our customers elite germplasm it is.
Price has been running through our technician.
Once the molecular conformation of the edit is complete.
We validate the quality of that.
The efficiency of the trials and ensure the late line.
Equal to what we initially received with the solid exception, albeit at three Meg.
This quality assurance is absolutely critical for all customers.
Peter Beetham: We proceed to generate a small supply of seeds to hand back to the customer so they can begin their commercialization process. We envision this entire process lasting between 18 to 24 months. It is important to note that at Cibus, our early work on our developed traits has been completed in growth rooms, greenhouses, and field trialing over many years to showcase the process prior to entering the high throughput editing process with customers to net. This early work we have completed provides excellent guidance for our customers on how we can accelerate their commercial process. Cutting down what has historically been a decades-long process to a few years is truly revolutionary and underpins our strategy to build a scaled, high margin, high free cash flowing business. Back to you, Rory. Thank you.
We then interest you to generate a small supply stage to hand back to the customer. So they can begin their commercial.
Foundation question.
We envision this in time.
Tri state's lasting between 18 to 24 months.
It is important to note.
But I'd say this out really with on how developed site has been completed and grocery items greenhouses and field trialing.
For many years to showcase the process prior to entering the high throughput editing process with customers.
This early work we have completed provides excellent guidance for our customers on how we can accelerate that.
<unk> commercial products there.
Cutting down what has historically been a decade long process to a few years is truly revolutionary and underpins our strategy to build a scaled high margin high free cash flowing business.
Back to you. Thank you.
Rory Riggs: Thanks, Peter. In summary, our commercialization efforts are well underway and are centered around advancing five traits with applications in three major crops, rice, canola, and soybean. Combined, we believe this represents an addressable market opportunity of over $1 billion in royalties, and our three crop, five trait model is just the beginning of what our capabilities can ultimately address. In addition to the five trait, three crop commercialization process, there are other elements that are also important to our commercialization efforts. The summer in agriculture is a key time for field studies, and this year we had an extensive field trial schedule for each of our traits. We also work with our customers in the fields as we work together to launch our three developed traits.
Thanks, Peter and summary, our commercialization efforts are well underway and are centered or dancing.
Lansing five trades with applications in the three major crops rice canola and soybean.
Combined we believe this represents an addressable market opportunity of over $1 billion in royalties and our three crop five trade model is just the beginning of what our capabilities can help fulfill the address.
In addition to the five trades re crop commercialization process there are other elements.
So important to our commercialization efforts.
The summer in Agriculture is a key time for field studies and this year, we had an extensive field trial schedule for each of our trades.
We also work with our customers in the fields as we work together to launch our <unk> III to fill up trades.
Rory Riggs: Additionally, in Q3, we established our first multi-locational field network for Sclerotinia white mold resistant testing of various modes of action that are progressing through our pipeline. This field performance network is critical to advance and demonstrate the efficacy of existing and additional modes of action for Sclerotinia resistance. 2023 has also been a key year in the development of a new global regulatory regime for gene editing technology, specifically gene editing technology that does not use transgenes. In recent years, we have seen the introduction of policy enabling the use of gene editing without the use of transgene in multiple countries around the world. Most recently, on 5 July, the EU College of Commissioners adopted the European Commission proposal on the regulation of plants obtained from new genomic techniques, often referred to as NGTs.
Additionally, in the third quarter, we established our first multi locational deal that works for spirits in your weight Volcker system testing of various modes of action.
That are progressing through our pipeline.
This field performance network is critical to advance and demonstrate the efficacy of existing and additional modes of action per square 10 year resistance.
Korea has also been a key year in the development of a new global regulatory regime for gene editing technology, specifically gene editing technology that does not use transfusions.
In recent years, we have seen introduction of policy.
With gene editing without the use of <unk> in multiple countries around the world.
Most recently on July 5th EU Colleges Commissioners adopted the European Commission proposal and the regulation of plants obtained the genomic techniques often referred to as in GTS.
Rory Riggs: The proposed regulation identifies a conventional-like category of NGT products that would be regulated as conventional varieties, bringing EU closer to that of trading partners in North and South America, Australia, and Japan. In the proposal, the commission highlights the potential of NGTs to contribute to a more sustainable agriculture, climate resilience, and food security. Under this proposal, products from Cibus's gene editing platform would be considered conventional-like. The EU is important for many reasons. First, it is a critical bellwether for the rest of the world. Second, it represents over 100 million acres that have not had access to GMO trait technologies. Third, there are approximately 20 million acres of winter oilseed rape grown in Europe, which ties directly into our own strategy. Our PSR trait has been developed for this market, and we began field trials for this trait in the UK in 2023.
Post regulation identifies conventional like category and GT products that would be regulated as convention varieties.
Bring you closer to that of trading partners.
All of America, Australia, and Japan.
And the proposal the commission highlights the potential of N. GT is to contribute to a more sustainable agriculture climate resilience and food security.
Under this proposal products from <unk> gene editing platform would be considered conventional lake.
The EU is important for many reasons first it is a critical bellwether for the rest of the world.
It represents over 100 million acres.
The GMO trait technologies.
Third there are approximately 20 million acres of winter oilseed rape grown in Europe, which tries to directly into our own strategy.
<unk> trade has been developed for this market and we began field trials for this trait in the UK in 2023.
Rory Riggs: The market is also suitable for our other advanced traits within our canola pipeline. These are major steps in the progression of our products and technology on a global basis. We will continue to monitor and update the progress on these regulatory advances as they occur, but we're on target for gene editing technology to be a globally approved methodology for advancing plant traits. Now I'll pass the call on to Wade to briefly review our financials.
The market is also suitable for other advanced trades within our colonial pipeline.
These are major steps in the progression of our products and technology on a global basis, we will continue to monitor and update the progress on the regulatory advances.
Curve, but we're on target for gene editing technology to be globally approved methodology for advancing plant trades now I'll pass the call onto way to breakthrough will review our financials.
Wade King: Thank you, Rory. Looking at our financials for Q3, cash and cash equivalents was $31.9 million as of 30 September 2023. We believe our cash and cash equivalents will enable us to fund planned operating expenses and capital expenditure requirements into Q1 2024. R&D expense was $17.5 million for Q3 2023, compared to $3 million in the year ago period. The increase was primarily related to increased lab supply and facility expenses, an increase in employee headcount, and an increase in stock-based compensation expense for restricted stock awards. SG&A expense was $8.8 million for Q3 2023, compared to $3.2 million in the year ago period.
Thank you Laurie.
Looking at our financials for the third quarter.
Cash and cash equivalents was $31 9 million as of September 32023.
We believe our cash and cash equivalents will enable us to fund planned operating expenses and capital expenditure requirements into the first quarter of 2024.
R&D expense was $17 5 million towards the third quarter of 2023.
Two 3 million.
The year ago period.
The increase was primarily related to increased lab supply and facility expenses.
An increase in employee head counts and an increase in stock based compensation expense for restricted stock Awards.
SG&A expense was $8 8 million for the third quarter of 2023.
Compared to $3 2 million in the year ago period.
Wade King: The increase was primarily related to an increase in headcount, increased consulting and legal fees, and an increase in stock-based compensation expense for restricted stock grants. Non-operating expense was $0.9 million for Q3 2023, compared to non-operating income of $0.3 million in the year-ago period. The decrease was due to changes in the fair value of the liability classified Class A common stock warrants. Net loss was $34.5 million for Q3 2023, compared to a net loss of $6 million in the year-ago period. For additional details about our financials for Q3 2023, please refer to our press release and filings with the SEC. That concludes our financial discussion. Rory, back to you for your closing remarks.
The increase was primarily related to an increase in head count.
<unk> consulting and legal fees.
Increase in stock based compensation expense for restricted stock grants.
Non operating expense.
<unk> 9 million for the third quarter 2023, compared to non operating income of <unk> 3 million and a year ago period.
The decrease was due to changes in the fair value liability classified class a common stock warrants.
Net loss was $34 5 million.
Third quarter of 2023 compared to a net loss of 6 million in the year ago period.
For additional details about our financials for third quarter of 2023.
Please refer to our press release and five <unk>.
That concludes our financial discussion worry back to you for your closing remarks.
Rory Riggs: Thanks, Wade. Many thanks to everyone for listening in. I can't tell you how excited we are to see what the future brings for Cibus. We believe that we are at a historic inflection point where we can, for the first time, bring rapid innovation to an industry that is hungry to solve the world's food shortages. With tailwinds from an improved regulatory environment and breakthroughs in trait development, our experienced team at Cibus is executing on the opportunities ahead of us as we continue to advance deployment of our traits to our customers' elite germplasm to enhance their product offerings for the benefit of their farmer customer. We really look forward to updating you on the next call. Operator, that concludes our prepared remarks. You may now open up the call for Q&A.
Thanks Wade.
Thanks to everyone for listening in.
I can't tell you how excited we are to see what the future brings receivers.
We believe that we are a dork inflection point, where we can for the first time bring rapid innovation towards industry is hungry to solve the world's food shortages.
Tailwind from an improved regulatory environment, and breakthroughs and trait development.
Experienced team at CBS is executing on the opportunities ahead of us as we continue to advance the deployment of our traits to our customers' elite germplasm to enhance their product offerings for the benefit of their farmer customer. We really look forward to updating you on the next call operator that concludes our prepared remarks.
I'll open up the call for Q&A.
Operator 4: Thank you. Our first question is from the line of Bobby Burleson from Canaccord. Please go ahead.
Thank you if you would like to register a question. Please press the one followed by the four on your telephone.
We'll hear a three tone prompt to acknowledge your request and if your question has been answered and you would like to withdraw your registration. Please press the one followed by the three.
And our first question is from the line of Bobby Burleson from Canaccord. Please go ahead.
Bobby Burleson: Thank you. Hi, Rory and team. I guess my first question is just around helping us understand how to prioritize some of the efforts currently underway. If we can just look at some of the commercialization progress that you guys announced that took place over the quarter. Maybe help us rank that in terms of significance by total addressable market opportunity or timeline or both.
Thank you.
Hi, Mary and team.
So yes.
I guess my first question is just around <unk>.
Helping us understand how to prioritize some of the.
Efforts currently underway. So if we can just look at.
Some of the commercialization process progress that you guys announced.
That took place over the quarter.
Maybe help us rank that in terms of significant bye.
The total addressable market opportunity or.
Timeline or both.
Rory Riggs: Thanks, Bobby. That's a great question. We have these five traits, we totally realize they're prioritized, and our prioritize is really these three development traits. The emphasis here is saying, what happened in the last quarter to get rice further along, and what happened in the last quarter to get pod shatter further along? I'll let Peter talk to some of it, but because of the work we've done in rice, we now have really big demand in Latin America, and we've already signed one big customer, which we think represents ± three and a half million acres, and we have a number of others right in the target. The real progress has been the development we've done in the commercial customers.
Thanks, Bob.
I think that's a great question.
We have these five trades.
Totally realize they're prioritizing in our prioritized is really these three developed trades and so the emphasis here is what happened in the last quarter to get rice further along but what happened in the last quarter to get pod chatter further along and.
I'll, let Peter talk to some of it but.
Because of the work we've done in rice.
We now have really big debate, but Latin America.
We've already signed one big customer, which we think represents plus or minus 3 million acres that we have a number of others rather than the target and so a real progress has been the development. We've done in the commercial customers. So these are customers who are now in the process of sending us their germ plasm.
Rory Riggs: These are customers who are now in the process of sending us their germplasm and us putting our traits in their germplasm. Our goal is over the next year to be able to take these germplasms and get it back to them with their traits so they could launch it. The progress, hopefully you'll follow, is the contracts we're signing and acres that go with it and how fast we can turn around these germplasms. The goal in this business is to get these germplasms in people's crops so they can bulk up alone. We're part of the launching process, so when we ship back, we'll have a pretty good sense of the timing of when they bulk up and when they go. On pod shatter, what's really interesting about pod shatter is first, that we have 10 traits.
Putting our trades and their germplasm.
And so.
And our goal is over the next year to be able to take these germplasm to get it back to them with their trade so that could launch it in enough progress hopefully youll follow as the contracts, we're signing of acreage that go with it and how fast we can turnaround the germ plasm.
The goal in this business is to get these germ plasm and People's crops, So Nathan bulk up alone.
We're part of the launching process. So when we ship back we'll have a pretty good sense of the timing why do they bulk up and when they go in and touch.
Shatter.
What's really interesting about <unk> first.
Rory Riggs: We've edited them and we're at different process of launching back. I'd like Peter to talk about the big thing in pod shatter is the building we were now able to do with field studies and field studies with the customers and the combination of getting them their germplasm in our field studies. We have this model, again, all three of these traits are going to be ready for planting around the same time. For each one of these things, we need to be really clear about the things we're doing to get them ready for that time and two, be able to say whether things got delayed, more importantly, tell you why we're encouraged by where they are and how to think about revenues. Peter, you want to throw a little bit on plants and field studies?
We have 10 trades with additive or a different process of launching back but like Peter to talk about the big thing in part shatter is.
The building, we were now able to do with field studies and field studies with the customers and the combination of getting them their germplasm into field studies.
We have this model again, all three of these trades are going to be ready to your planning around the same time, but for each one of these things.
To be really clear about the things, we're doing to get them ready for that time.
And two.
Be able to say whether things got delayed but more importantly to tell you why we're encouraged by where they are and how to think about revenues Peter you want to throw a little bit on plants.
Yes.
Peter Beetham: I do. Thanks, Bobby, for the question, and thanks, Rory. I think the best way to think about our progress, and I'm going to specifically talk about canola pod shatter, is that as Rory mentioned, we have 10 customers whose genetics, and I've mentioned it on the call, elite germplasm, in our hands, and we're in the midst of transferring back to that. Far in 2023, we've transferred two of our customer lines back. The whole group of elite genetics that we have in hand equates to accessing as much as 20 million acres over time. What's exciting for us is that those transfers are starting to occur, and then the field trials that we're doing with the canola hybrids with pod shatter trait in them, were very successful this last summer.
I do.
Thanks, Robbie for the question and thanks Rory.
I think the best way to think about our progress.
And I'm going to specifically talk about granola Pud Shadow is that as Barry mentioned, we have 10 customers.
<unk>, whose genetics and I've mentioned it on the call elite germplasm.
In our hands and we're in the midst of transferring back to that so.
So far in 2023 would transfer to the customer lines back.
The whole group of elite genetics that we have in our hand equates to accessing it as much as 20 million acres over time, but what's exciting for us is that that transfers the starting to occur.
And then.
L trials that we're doing.
With the canola hybrids with potsherd with Triton.
<unk>.
We were very successful this last summer.
Peter Beetham: We're so excited to see the traits in the field in customer genetics. This winter, we'll be looking at canola hybrids in winter nurseries and really move to that next level of pre-commercialization performance evaluation in 2024.
So excited to see that in the field and customers genetics.
And then.
This winter, we will be looking at NOLA hybrids.
In winter nurseries, and really move to that next level of pre commercialization performance evaluation in 2024.
Rory Riggs: Thanks, Peter. Bobby, the other thing, we're so focused on these three traits and two crops, we just can't ignore the fact that we're so excited about soybeans. We're doing it in GDM germplasm, but we really are excited that we'll be able to finish that this year. Once we do that, it's really this big opportunity that suddenly, we believe once people think we have this single-cell model that regenerates back into a plant in a soybean, that we have a lot of customers who are in this soybean business. There's just a really big opportunity to build this business. Does that address your question, Bob?
Thanks, Peter and then probably the other thing we were so focused on these three crops in St. Pete Tracy two crops.
Kansas ignore the fact that we're so excited about soybean and we're doing it in GBM germ plasm, but we really are excited that we'll be able to finish that this year.
And once we do that it's really the big opportunity that suddenly we believe one of the people think we have this single cell model that regenerates back into a flat soybean that we have a lot of customers from display being built there is just a really big opportunity to build this business.
That's super helpful.
Helpful.
Bobby Burleson: Yeah. That's great. Just to follow up, obviously this EU draft, on their proposed regulatory treatment of what I was calling NBTs, but I guess, there are lots of acronyms. It sounds very positive. I'm wondering, can you kind of draw a parallel between what they're talking about doing and what Canada's already done? I guess, where is the demand coming from in the EU? Is this something that's been in the works for a long time in order to change these regulations? Are they constrained in some ways, food security-wise or reevaluating how they're regulating other aspects of their food system, and this is being pulled along with it?
Yes, that's good.
Great and then just a follow up.
Obviously this EU draft on their proposed regulatory treatment of.
And that was calling and Bt's cut I guess, the other lots of acronyms.
Sounds very positive.
And I'm wondering can you kind of.
Trump parallel between what they're talking about doing it and what Canada is already done.
And then.
What I guess, where is the demand coming from in the EU is this.
Something thats been kind of in the works for a long time in order to change. These regulations are they constrained in some ways food security wise or.
Reevaluating.
How they're regulating other aspect similar food system that is being pulled along with it.
Rory Riggs: Thanks. Peter, let me take the overview and let you go to the specifics with the customers, because I think it'd be helpful for them to understand the actual customers we have in canola and how broad our demand is from the customers in canola, and the fact that we can now do studies in the UK. The biggest shock we have, UK's been under a 3-year process to try to change their laws so that gene editing that doesn't include transgenes gets treated as conventional breeding, and there's really big consensus across Europe. The productivity in Europe has so gone down, not having any GMOs at all, and so they need this law. When they did their safety study, they basically said our technology was safe, and they drew it.
Thanks, Peter let me take the.
Overview I'll, let you go to the specifics with the customers. So I think it would be helpful for them to understand the actual customers, we havent canola and how broad our demands from our customers in canola and the fact that we can out of these studies in the UK, but the biggest shock we have UK has been under a three year process to try to change their laws. So that gene editing that doesn't include <unk>.
<unk> gets treated as conventional breeding and there's really big consensus across Europe there.
The productivity in Europe is so gone down not having any gmos at all and so they need this law and we weathered it just safety study. They basically said our technology is safe and they drew it but that was surprised us was.
Rory Riggs: What surprised us was, this was probably 3 months before when we said that in our press release, 3 months before we thought it would happen. In the press release, they talked about taking it to Parliament in February, we were thinking June. We're pretty excited that there's really not just forward progression, but they're trying to speed up the process to get it behind us. Peter, you might go, if that's helpful. It's really quite an encouraging moment for all of us. The UK haven't passed it, so we can now do field studies in the UK is a big deal, because it allows us to start the progression of these products that are grown in Europe. Peter, you want to add to the customers?
This was probably three months before we said that in our press release three months before we thought it would happen and then in the press release, they talked about taking it to parliament in February with June So we're pretty excited that.
Theres really not just forward progression, but theyre trying to speed up the process to get it behind us.
Peter you might go if that's helpful. It's really quite an encouraging moment for all of us.
In the U K you haven't asked it so I'll do field. So do you see U K is a big deal because it allows us to start the progression of these products that are grown in Europe, Peter you want to add to the customers.
Peter Beetham: Yeah, exactly, Rory. I think, Bobby, your question around this is really on point because it's clear that the EU is trying to accelerate this regulatory, which is not the normal state of affairs. A number of our customers are based in Europe and are very excited with the opportunity to bring traits to market. The whole of Europe is a 100-million-acre market that just hasn't had a lot of innovation in the last 30 years. To the point about improving sustainable agriculture, climate resilience, and food security, they are big drivers for regulatory. These tailwinds to bring improved products onto the marketplace is really seen by our customers as a huge step. The fact is, three of our customers' genetics and the trials in the UK over the winter into the spring of 2024.
Yeah, exactly very I think.
Bobby Your question around this is really on point because.
It's clear.
Clear that the EU.
Uh huh.
He is trying to accelerate this regulatory which is which is not the normal.
State of affairs, and so a number of our customers.
In Europe and are very excited.
The opportunity to bring traits to market now this is the whole of Europe as 100 million acre market just hasn't had a lot of innovation in the last 30 years.
To the point about improving sustainable agriculture climate resilience and food security.
Big drivers for regulatory.
These tail winds.
For to bring improved products onto the marketplace is really seen by our customers as a huge step.
The fact is with.
Many of our customers genetics and the trials in the U K.
Over the winter into the spring of 2024 that is a first for canola winter.
Peter Beetham: That is a first for canola winter oilseed rape, and it's exciting to see that because I think that alignment globally, and you mentioned Canada in your question, is seeing a lot of progress on the regulatory front for harmonizing where the regulatory agencies are on in Europe, they call them new genomic techniques, but essentially products from gene-edited technology, and specifically ones like Cibus, where we have a non-transgenic process and a non-transgenic product. They're harmonizing around the world, and that really opens up global markets for someone like Cibus.
Winter Oilseed rape.
And it's exciting to see that because I think that alignment.
Globally, you mentioned, Canada in your question.
Is seeing a lot of progress on the regulatory front for harmonizing with the regulatory agencies are on a well you know in Europe I call them, new genomic techniques, but essentially products from gene edited.
LNG and specifically ones like Steve is where we have a non transgenic process and a non transgenic product or they are harmonizing around the world and that really opens up global market for someone like seamless.
Rory Riggs: We have a number of-
That's really helpful.
Bobby Burleson: Yeah, go ahead.
Yeah, Yeah go ahead.
Rory Riggs: We have a number of customers under contract already, and the neat thing is to think about this 100 million acres that's never had a wheat trait, ever. We have three now, so it's a big opportunity for us. I'm sorry. I didn't get the instructions.
Under contract already.
And the neat thing is to think about this 100 million acres has never had a wheat trade ever.
We have three now.
Big opportunity for Us I'm sorry.
Many of the distractions.
Bobby Burleson: No, that's great additional color. To be clear, this also would cover imports into the EU?
No that's great additional color and to be clear. This also would cover imports into the EU.
Peter Beetham: That is correct.
That's correct.
Rory Riggs: Yes. The key to these laws are once you do that, it means when we develop a trait, it'll be treated like conventional breeding coming into Europe. For people who aren't familiar with it, Europe treats GMO products almost like drugs, and it takes three to five years to get approval. Suddenly, everything we develop will have clear export approval. I think that it's going to be a big moment here in the United States, and boy, it'll be a big moment for soybean to be able to introduce new traits we don't have.
The key to these laws are once you do that it means when we develop a trade it it'll be treated like conventional breeding coming into Europe for people, who aren't familiar with it Europe treats GMO products almost like drug. So it takes three to five years to get approval suddenly everything we develop.
Clear export approval and then I think that is.
It's going to be a big moment for the industry, but it will be a big moment for soybean.
To be able to introduce.
Sure.
Bobby Burleson: Yeah, understood. Yeah, this could be huge. Maybe just looking at where there is GM technology existing in germplasm, is there interest simply just because of the speed at which you can introduce a trait, and at a lower cost, where you will potentially be stacked on some of these GM seeds as a significant part of what you are doing over time?
Yeah understood.
Could be huge.
And maybe just.
Looking at where there is GM.
Technology.
This thing in germplasm is there.
Interest simply just because of the speed at which you can introduce a trade.
And at a lower cost.
You'll potentially be stack on <unk>.
<unk>.
Yeah.
It has a significant part of what Youre doing overtime.
Rory Riggs: It totally is. Pod shatter, they don't have that trait, and that's not one that's all about speed. The fact of the matter is, our team has actually developed real traits. The first part is there's actually real traits. The speed thing is the fact that literally if you send us your germplasm in canola, now that Peter and Greg have figured out how to take a one cell from that germplasm, edit it, and grow it. That if you send us your germplasm in 18 to 24 months, we can have our trait in your germplasm ready to do field trials. Peter, you want to add to that? That's really.
It totally is but pods chat or they don't have that trade and that's that's not one that's all about speed the fact that matters.
Our team had actually developed a real trades. So the first part of this there's actually real trades and then the speed thing is is the fact that that.
Literally if you send us your germplasm.
All of the other Peter and Greg I figured Las Vegas single cell from that germ plasm added it and grow it does your germplasm in 18 to 24 months, we can have our trait in Basel.
Ready to field trials.
And then Peter you on that.
It doesn't really.
Bobby Burleson: It seems like that's an important distinction, right?
It seems like that's an important distinction right because.
Rory Riggs: Yeah
Bobby Burleson: People might be tempted to think this is purely gene-edited seeds. The market's much bigger, right? We're talking about pretty much all seeds where your technology has relevance.
People might be tempted to think this is purely.
Gene edited.
Seeds, but the market is much bigger right because we're talking about pretty much all seeds, where your technology has relevance.
Rory Riggs: Yeah. Totally relevant.
Yeah, that's something that in.
Peter Beetham: Let me add in, Bobby, because I think you've hit on a really important point. For us who have been in ag tech for over 30 years, the recognition is that there was limitations to GMO, major limitations on what you could do. In my mind, it's like Windows 95. It's very old technology. Bringing forward gene-edited traits is just bringing forward traits that are really valuable in the market. There's markets where we can access, but where there's been a complete barrier to getting GMOs in, where you're free and clear with gene editing. There's going to be other markets, more global markets, perhaps in North and South America, where we'll be adding traits to genetics that already have traits. The expansion and opportunity is huge.
Yes, Bobby.
I think you hit on a really important point.
Okay.
Okay.
30 years.
The recognition is that.
No there was limitations to GMO major limitations on what you could do it.
In my mind, its like Windows 95, it's very old technology.
Bringing forward gene editing is just bringing forward trials that are really valuable in the market. So.
Theres markets, where we can exit that is where there's been a complete barrier to getting gmos in the way you're free and clear with gene editing and then there's going to be other market small global market perhaps.
In North and South America, the way it will be adding traits to.
Genetics that already have trades and so.
That's right.
The expansion opportunity is huge.
Peter Beetham: The fact is that gene editing can address traits like Sclerotinia, like white mold, disease resistance, where other technologies could not in the past. Not only does it open up global markets, it opens up opportunities and traits that were never able to be done using other technologies.
That is the gene editing can address.
Sites like <unk> like white mold disease resistance.
All of the technologies could not in the past.
Not only does it open up global markets it opens up opportunities of trade.
Able to be done using other technologies.
Bobby Burleson: Well, thank you both.
Rory Riggs: Peter-
Bobby Burleson: I'm going to let somebody else ask a question here.
Well thank you both.
Somebody else ask a question here.
Rory Riggs: Oh, dude, totally.
Bobby Burleson: You guys have asked four or five in a row.
They're totally about SaaS for a five in a row.
Peter Beetham: Thanks, Bob.
Bobby Burleson: Thank you.
Well thank you.
Rory Riggs: All good. Peter, while he's breaking, can you tell about India? India is such a big marketplace for both soybean and rice.
All good.
But Peter all these breaking you can you tell me how about India, India is such a big marketplace for both soybean and and and.
Yes.
Peter Beetham: Yeah. I think India has nearly 100 million acres of rice. It's a very fragmented market, but it has a huge appetite for traits. Just recently, Bayer released that they are targeting 20% of that market, so 20 million acres around, which is what they call direct seeded market in India. That's just an example of where a trait like herbicide tolerance is something you really need to be able to do direct seeded rice. There's an appetite not only for opening up the markets to better genetics, but also genetics with traits. India is the classic example of an emerging market in agriculture that will take on traits in rice as well as canola. It's a little bit different in India, different genetics than what's in North America, but it is a very close relative.
Yeah I think.
India is nearly 100 million acres of rice.
And.
It's a very fragmented market, but it is it is has a huge appetite for trade and you know just recently.
But released.
That they are targeting 20% of that market. So 20 million acres around which is what they call direct seeded market in India. That's just an example of where you can.
Attrite like herbicide tolerance is something you really need to be able to do direct seeded Ross so there's that.
Appetite not only for opening up the market to better genetics, but also genetics. We've tried so India is that the classic examples in emerging market.
In agriculture that will take on traits in rice as well.
Canola.
It's a little bit different in India than.
Different genetics than what's in North America, but it is a very close relatives.
Rory Riggs: Thanks, Peter. Is it next? I apologize.
Thanks Peter.
I apologize.
Operator 4: Our next question is from the line of Laurence Alexander with Jefferies. Please go ahead.
And our next question is from the line of Laurence Alexander with Jefferies. Please go ahead.
Kevin Estok: Hi. Good evening. This is Kevin Estok on for Laurence. Just one question from me.
Hi, Good evening this is Kevin Estok on for Laurence.
Just one question for me for me I, just don't want it.
Kevin Estok: Sure.
Kevin Estok: To what extent has the volatility in the ag market, I guess, distracted customers from research partnerships or changed our timetable and our milestones for next year?
<unk> has a volatility yes.
What extent has the volatility in the AG market.
I guess distracted customers from research partnerships or change your timetable and and our milestones for next year.
Rory Riggs: I'll give a little one. I'll leave it to Peter on the volatility of the markets. The good news is that we're really focused on traits that are already developed, right, and we're trying to sell to. We're not trying to focus on new research agreements as much. We want to see where we can develop what we have go out there. We haven't seen decrease, but more increase because people see we actually have actual traits they can buy. Peter, you want to add to that?
I was going to live and I'll leave it to Peter on the volatility of the markets. The good news is that we're really focused on.
Traits that are already developed and we're trying to sell to so we're not trying to focus on new research agreement as much we wanted to see where we can develop but we have go out there and.
We haven't seen decrease by more increase because people see we actually have.
Actual trades today Goodbye Peter you on it.
Peter Beetham: No, I think the volatility is there for sure. I think where traits play a role is in the seed industry for increasing farmers' productivity. The appetite for our traits because is increasing. We see demand from our customers of additional genetics that they would like to have traits in, so that they can deliver better profits for farmers by increasing their productivity. The volatility actually, in my mind, accelerates the demand and requirements for technologies like Cibus is delivering to the seed customers.
I think the volatility is there for sure I think.
We will try to play our role is in the seed industry for increasing prime is productivity.
So.
The appetite for outright because is increasing we see demand.
From a customers'.
Additional genetics that they would like to have traits in.
So that they can deliver.
Better profit Saddam is by increasing their productivity so the volatility actually in my mind.
It accelerates the demand and requirements for technologies like Steve This is delivering to the customers.
Kevin Estok: Got it. Okay. Thank you very much.
Got it okay. Thank you very much.
Rory Riggs: It is a distinction between strict yield stuff and specific trait stuff, right? Specific productivity aspects of traits, which has been interesting, I think. Thanks so much.
It is a distinction between strict yield stuff and specific.
Trade stuff right.
Vic.
Specific productivity aspects of trade, which has been interesting I think but thanks so much.
Kevin Estok: Thank you.
No problem.
Okay.
Yeah.
Operator 4: Mr. Riggs, there are no further questions at this time. I will now turn the call back to you for closing remarks.
And Mr. <unk> there are no further questions at this time I will now turn the call back to you for closing remarks.
Oh.
Rory Riggs: Thanks, team, and thanks for the questions. I think that our goal in these calls now is to help you understand the progression. We have actual traits and because of that, every quarter, like this was the field study quarter, every quarter there'll be aspects to be able to track how well we are towards our goal of having seeds in the field being accessed by farmers. I think that the things we've really talked about are, one, besides mapping our progression, the two big things everybody's going to see is can we do soybean and can get it off? Because that's just a big value moment for us.
Thanks, Tim and thanks for the questions I think that our goal in these calls now is to help you understand the progression we have actual trades in and because of that every quarter. Like this was the field study quarters every quarter there'll be aspect to be able to attract how well we are towards our goal of having six in that field.
Being accessed by farmers and so I think that the things, we've really talked about our <unk>.
One.
Our mapping our progression the two big things everybody is going to see is can we do soybean and they can get it off because thats, just a big value moment for us and to Europe seems to be accelerating so as quick as we can get Europe behind us, but we'd become a real III crop fives trade business model and we've become truly global and we're really excited.
Rory Riggs: Two, Europe seems to be accelerating, so as quick as we can get Europe behind us, suddenly we become a real three crop, five trait business model, and we've become truly global, and we're really excited by it. The most important part is just sort of understanding our progression and following it. If you guys have any more questions, please call. It's a really exciting moment for us to be able to track. Peter, you want to add anything?
Got it.
And the.
The most important part of it is just sort of understanding our progression. Following those you guys have any more questions. Please call.
Really exciting moment for us for us to all the trucks, Peter you want to add anything or.
Peter Beetham: I think that's a good summation, Rory. It's definitely an inflection point for where we are.
And I think Thats, a good summation right.
Definitely I didnt quite well.
Where we are.
Rory Riggs: Cool. Thanks, guys. Thanks, team. I think we're done.
Cool Thanks, guys. Thanks, Tim I think we're done.
<unk>.
Operator 4: That does conclude your conference call for today. We thank you for your participation and ask that you please disconnect your lines.
That does conclude your conference call for today, we thank you for your participation and ask that you. Please disconnect your lines.
Hum.
[music].
Okay.
Okay.
[music].
